Know Cancer

or
forgot password

Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)


N/A
18 Years
N/A
Not Enrolling
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)


Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of
cancer mortality in the US. The incidence rate of HCC is increasing along with the
incidence of Hepatitis B and C which are known to promote HCC. Patients have a better
prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best
imaging modality for diagnosing HCC.

This study will compare standard MRIs and MRIs performed with a newly developed MR protocol
to determine if it is possible to more confidently diagnose HCC.


Inclusion Criteria:



- known hepatocellular carcinoma

- undergoing MRI of the liver

Exclusion Criteria:

- Contraindication to MRI with IV contrast

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.

Outcome Time Frame:

One day: participants will have one MRI of the liver.

Safety Issue:

No

Principal Investigator

Orpheus Kolokythas, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Washington

Authority:

United States: Institutional Review Board

Study ID:

DI-2009-1

NCT ID:

NCT01215838

Start Date:

August 2010

Completion Date:

January 2012

Related Keywords:

  • Hepatocellular Carcinoma
  • HCC
  • hepatocellular carcinoma
  • Eovist
  • MR
  • MRI
  • magnetic resonance
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location